Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals
By Jie Lu, M. Liong, Zongxi Li, J. Zink, F. Tamanoi. Small, 2010
1,001 citations recorded by the source corpus.
Mesoporous silica nanoparticles (MSNs) are a promising material for drug delivery. In this Full Paper, MSNs are first shown to be well tolerated, as demonstrated by serological, hematological, and histopathological examinations of blood samples and mouse tissues after MSN injection. Biodistribution studies using human cancer xenografts are carried out with in vivo imaging and fluorescent microscopy imaging, as well as with inductively coupled plasma mass spectroscopy. The results show that MSNs preferentially accumulate in tumors. Finally, the drug-delivery capability of MSNs is demonstrated by following tumor growth in mice treated with camptothecin-loaded MSNs. These results indicate that MSNs are biocompatible, preferentially accumulate in tumors, and effectively deliver drugs to the tumors and suppress tumor growth.
Subfields: Biomaterials, Biomedical Engineering
View Paper: https://www.semanticscholar.org/paper/70751a5d09209135d872fa0bcc52ee1a462f4081
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- Fangqiong Tang
- Veronika Mamaeva
- Linlin Li
- D. Lombardo
- C. Sahlgren
- M. Kiselev
- Dong Chen
- M. Lindén
Citations in the corpus
- The Impact of Silica Nanoparticle Design on Cellular Toxicity and Hemolytic Activity (2011, neutral): “100 nm), lengths and aspect ratios (1, 2, 4, 8) were synthesized.”
- Mesoporous silica nanoparticles in target drug delivery system: A review (2015, neutral): “The residuals can be either removed or retained, therefore, the shrinkage during long-term storage can be minimized.[28]”
- Mesoporous silica nanoparticles in medicine--recent advances. (2013, background): “(tail vein) into nude mice bearing subcutaneous MCF-7 xenografts and also found efficient accumulation of MSNs in the tumors 4 and 24 h post injection [54].”